SPYRAL HTN-OFF MED: Renal Denervation Reloaded?

This work presented at the ESC Congress 2017 held in Barcelona, simultaneously published in The Lancet, seems to give hope to all those that still believe in renal denervation. Interim outcomes suggest that a more intensive denervation of renal arteries, carried out at the SYMPLICITY HTN-3 trial, could reduce blood pressure in patients with untreated mild to moderate hypertension.

Intentando reducir la insuficiencia renal post TAVI

Compared to those receiving placebo at procedure (sham procedure), denervation with the new multi-electrode catheter Symplicity Spyral (Medtronic) resulted in superior reduction of 24 h systolic blood pressure (some 5 mmHg lower) and 3 month diastolic blood pressure (some 4.4 mmHg lower).

 

After the upsetting SYMPLICITY HTN-3, these results should be interpreted with cautious optimism, although it is obvious the shed light on renal denervation.


Read also: Patients with Resistant Hypertension: Nearly 50% doesn’t take medication”.


Actually, this is a small study (80 patients) with no statistical power for clinical final end points. In addition, study outcomes were assessed just at 3 months, response was variable, and even though blood pressure was significantly reduced, in absolute terms it was reduced only by 5 mmHg.

 

Patients included in this work were not under treatment (or had abandoned it) and had office systolic blood pressure between 150 and 180 mmHg. All eligible patients received renal angiography and were randomized to denervation or not. The angiography served as placebo procedure for the control group.

 

It is worth mentioning that there were no adverse events associated to the procedure, despite the more aggressive denervation performed in this study, compared to prior studies.

 

Original Title: Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomized, sham-controlled, proof-of-concept trial.

Presenter: Townsend RR.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....